GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Minority Interest

ORKA (Oruka Therapeutics) Minority Interest : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Oruka Therapeutics's minority interest for the quarter that ended in Dec. 2024 was $0.00 Mil.

Oruka Therapeutics Minority Interest Historical Data

The historical data trend for Oruka Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Minority Interest Chart

Oruka Therapeutics Annual Data
Trend Dec24
Minority Interest
-

Oruka Therapeutics Semi-Annual Data
Dec24
Minority Interest -

Oruka Therapeutics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Oruka Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Minority Interest
Comparable Companies
PGEN CGEM MNMD VERV RLAY PHAT TBPH OMER AUTL CRMD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
HQ1:Germany
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Website
https://www.orukatx.com
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.